Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 9/15/2021 (updated 4/3/2024)
The UNODC Regional Program Office for Eastern Europe (Kiev, Ukraine), in collaboration with the Humanitarian Action Fund (St. Petersburg, Russia), issues recommendations on web outreach for people who use drugs (PWUD), including people who use new psychoactive substances (NPS). Web outreach is a method of establishing contact, counseling, involving and retaining PWUD in harm reduction programs through websites, social networks, instant messengers, specialized forums, including Darknet platforms.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 10/21/2020 (updated 3/29/2024)
Created in 2007 by the outreach nursing team from the BC Centre for Disease Control (BCCDC) and co-produced with the National Film Board of Canada (NFB), Bevel Up is designed to give students and instructors in the healthcare field access to the knowledge and experience of pioneering practitioners.
Posted 10/12/2020 (updated 3/29/2024)
The present two-fold study “Speed Limits – Harm reduction for people who use stimulants” significantly contributes to closing the gap of knowledge about which existing harm reduction interventions are effective for people who use stimulant drugs.
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.